

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES  
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

## 144: Filer Information

Filer CIK 0001785299  
Filer CCC XXXXXXXXX  
Is this a LIVE or TEST Filing?  LIVE  TEST

### Submission Contact Information

Name  
Phone  
E-Mail Address

## 144: Issuer Information

Name of Issuer Frequency Therapeutics, Inc.  
SEC File Number 001-39062  
Address of Issuer 75 HAYDEN AVENUE  
SUITE 300  
LEXINGTON  
MASSACHUSETTS  
02421  
Phone 781-315-4600  
Name of Person for Whose Account the Securities are To Be Sold Loose Christopher R.

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Former Officer

## 144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	1425	934.37	35751956	08/09/2023	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

## 144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition	Name of Person from this	Date Donor	Amount of Securities	Date of Payment	Nature of Payment *
--------------------	-------------------	-----------------------	--------------------------	------------	----------------------	-----------------	---------------------

	Transaction	Whom Acquired	a Gift?	Acquired	Acquired
Common	08/08/2023 Restricted Stock Vesting	Issuer	<input type="checkbox"/>	1425	08/08/2023 Compensation

\* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

## 144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Christopher Loose 75 Hayden Avenue Suite 300 Lexington MA 02421	Common	07/06/2023	1384	469.73
Christopher Loose 75 Hayden Avenue Suite 300 Lexington MA 02421	Common	07/07/2023	1306	467.94
Christopher Loose 75 Hayden Avenue Suite 300 Lexington MA 02421	Common	07/10/2023	1304	487.57
Christopher Loose 75 Hayden Avenue Suite 300 Lexington MA 02421	Common	07/11/2023	1363	507.31
Christopher Loose 75 Hayden Avenue Suite 300 Lexington MA 02421	Common	07/12/2023	1335	521.18
Christopher Loose 75 Hayden Avenue Suite 300 Lexington MA 02421	Common	07/13/2023	1329	521.23
Christopher Loose 75 Hayden Avenue Suite 300 Lexington MA 02421	Common	07/14/2023	906	534.63
Christopher Loose 75 Hayden Avenue Suite 300 Lexington MA 02421	Common	07/17/2023	1415	947.77
Christopher Loose 75 Hayden Avenue Suite 300 Lexington MA 02421	Common	07/18/2023	1484	827.92
Christopher Loose 75 Hayden Avenue Suite 300 Lexington MA 02421	Common	07/19/2023	1335	861.74
Christopher Loose 75 Hayden Avenue	Common	07/20/2023	1361	871.86

Suite 300 Lexington MA 02421 Christopher Loose 75 Hayden Avenue Suite 300 Lexington MD 02421	Common	07/21/2023 1333	814.86
Christopher Loose 75 Hayden Avenue Suite 300 Lexington MA 02421	Common	07/24/2023 1438	781.55
Christopher Loose 75 Hayden Avenue Suite 300 Lexington MA 02421	Common	07/25/2023 1390	694.58
Christopher Loose 75 Hayden Avenue Suite 300 Lexington MA 02421	Common	07/26/2023 1329	679.38
Christopher Loose 75 Hayden Avenue Suite 300 Lexington MA 02421	Common	07/27/2023 1373	722.47
Christopher Loose 75 Hayden Avenue, Suite 300 Lexington MA 02421	Common	07/28/2023 1344	623.35
Christopher Loose 75 Hayden Avenue Suite 300 Lexington MA 02421	Common	07/31/2023 1329	668.22
Christopher Loose 75 Hayden Avenue Suite 300 Lexington MA 02421	Common	08/01/2023 1397	682.43
Christopher Loose 75 Hayden Avenue Suite 300 Lexington MA 02421	Common	08/02/2023 1293	671.45
Christopher Loose 75 Hayden Avenue Suite 300 Lexington MA 02421	Common	08/03/2023 1378	783.81
Christopher Loose 75 Hayden Avenue Suite 300 Lexington MA 02421	Common	08/04/2023 1272	877.37
Christopher Loose 75 Hayden Avenue Suite 300 Lexington MA 02421	Common	08/07/2023 1413	968.47
Christopher Loose 75 Hayden Avenue Suite 300 Lexington MA 02421	Common	08/08/2023 1438	968.78

## 144: Remarks and Signature

Remarks

Date of Notice 08/09/2023

**ATTENTION:**

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the

securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature            /s/Wade Moss, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact  
                              for Christopher Loose

***ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)***